Health Technology · Pharmaceuticals: Major · NSE: GUFICBIO · data 2026-10-09

Gufic Biosciences Limited

Health check: Average (5.5/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹406.3

Market cap

₹4,046 cr

P/E

55.5

P/B

—

ROE

10.1%

ROCE

15.3%

Debt / equity

0.61

Dividend yield

0.02%

1-year return

12.3%

52-week high

₹467.8

52-week low

₹268

Operating margin

13.6%

Growth

Revenue (last 12 months)	₹981 cr
Net profit (last 12 months)	₹73 cr
Sales growth, 3 years (yearly)	11.0%
Profit growth, 3 years (yearly)	-6.9%

Chart patterns

Double top — forming (key level ₹395.05)

Similar companies

SMS Pharmaceuticals Limited (SMSPHARMA) · Zota Health Care Ltd. (ZOTA) · Aarti Drugs Limited (AARTIDRUGS) · Unichem Laboratories Limited (UNICHEMLAB) · Kwality Pharmaceuticals Ltd (KPL)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open GUFICBIO in NSE Scanner →